隆平高科(000998) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit of 90 million CNY for the first half of 2024, a turnaround from a loss of 120 million CNY in the same period last year [4]. - Basic earnings per share are projected to be 0.0683 CNY, recovering from a loss of 0.0911 CNY per share in the same period last year [4]. Revenue Growth - The company's revenue from the rice industry increased by over 20% compared to the same period last year, contributing an additional net profit of approximately 65 million CNY [6]. Investment Income - The company anticipates a non-recurring investment income of about 340 million CNY from the transfer of 10.94% equity in Longping Biotechnology to a strategic investor [6]. Financial Expenses - The company reported a foreign exchange loss of approximately 280 million CNY due to fluctuations in foreign currency loans, significantly increasing financial expenses compared to the previous year [6].